Johannes Duell
Oberdürrbacher Street 6
Wuerzburg, BY 97080, Germany
Wuerzburg, BY 97080, Germany
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 64 publications
Second-line treatment with tafasitamab and lenalidomide for relapsed/refractory primary cutaneous diffuse large B-cell lymphoma.
Journal: Leukemia & lymphoma
Published: May 22, 2026
CD20 expression dynamics in adult B-cell acute lymphoblastic leukemia and impact on anti-CD20 treatment.
Journal: Journal of hematology & oncology
Published: March 31, 2026
Epcoritamab monotherapy or epcoritamab with lenalidomide as first-line therapy for patients with diffuse large B-cell lymphoma (EPCORE DLBCL-3): primary analysis of an open-label, multicentre, randomised, phase 2 trial.
Journal: The Lancet. Haematology
Published: March 31, 2026
Tafasitamab plus lenalidomide and R-CHOP versus R-CHOP for first-line treatment of patients with high-risk diffuse large B-cell lymphoma (frontMIND): a global, phase 3, randomised, double-blind, placebo-controlled trial.
Journal: Lancet (London, England)
Published: March 18, 2026
Correction: Activity of CAR-T cells and bispecific antibodies in multiple myeloma with extramedullary involvement.
Journal: Blood cancer journal
Published: November 01, 2025
Multiomic and Longitudinal Dissection of Immune Dynamics Associated with Parkinsonism after Ciltacabtagene Autoleucel Therapy.
Journal: Blood cancer discovery
Published: July 31, 2025
Results of brexucabtagene-autoleucel for patients with relapsed/refractory Mantle Cell Lymphoma in the routine setting in Germany and Switzerland.
Journal: Bone marrow transplantation
Published: July 27, 2025
Last Updated: 09/26/2026